raised SCPK whose muscles subsequently reacted to halothane. However, a raised SCPK alone lacks specificity as an indicator of malignant hyperpyrexia:
(1) High values occur in many conditions without hyperpyrexia, e.g. muscular dystrophy, dystrophia myotonica, childbirth, cerebrovascular disease, thrombosis, gangrene, physical exercise.
(2) Patient No. 9 (C S, Table 2 ), with histological evidence of myopathy, developed contracture with halothane but had a normal SCPK. Patient No. 12 (D B) had a raised SCPK apparently related to cerebral diplegia but no myopathy.
(3) Myopathic patients with high SCPKs have received general aniesthesia involving halothane successfully. (4) The family of a fatal hyperthermia patient showed normal SCPKs (Reske-Nielsen & Kratholm 1971) .
No patient with raised SCPK should be given a general anxsthetic involving the known 'trigger agents' unless there is an obvious explanation for the high enzyme level. Susceptibility to malignant hyperpyrexia should be excluded by full clinical examination together with a motor point muscle biopsy (Harriman 1961) for histological and histochemical studies, and neuropharmacological tests to detect muscle contracture in vitro after administration of anasthetic agents as outlined by Ellis et al. 
Histopathological and Neurophannacological Aspects of Malignant Hyperpyrexia
The symptomless brother of a girl who died from malignant hyperpyrexia had a raised SCPK and some myopathic signs. Biopsy of the vastus medialis muscle was performed under local anesthesia and histology revealed a myopathy, and both halothane and methoxyflurane produced muscle contracture in vitro (Ellis et al. 1971) . These pharmacological results were so different from control responses that we thought our findings could represent a more specific test of the susceptibility to malignant hyperpyrexia than serum enzyme estimations. Methods: Seven patients from four families underwent muscle biopsy under local anmsthesia, with parenteral sedation produced by diazepam or promethazine. Nitrous oxide was used in 2 children. Table 1 shows the relationship of the patients to a deceased malignant hyperpyrexia victim -Case 4 is a survivor. All except Case 7, a volunteer, had raised SCPK activities before referral but Cases 5 and 6 had normal SCPK levels for our laboratory. Only Case 6 had neurological symptoms and these were ascribed to cerebral diplegia.
During the biopsy the motor point was identified (Harriman 1961 ) so that the muscle specimens would include the motor end-plate region. Muscle for pharmacological testing was kept in Krebs solution gassed with 5 % CO2 in 02 until assembled in a tissue bath kept at 37°C. Halothane (0.5-4 %) was added to the gas mixture and other drugs were added to the Krebs perfusate. Muscle contracture was detected by a transducer and recorded. The effects of procaine HCl (3.87 and 1.94 mmol) and caffeine citrate (2-8 mmol) on the contracture were also studied. Results: Although neurological signs attributable to myopathy were minimal, 5 patients had histological evidence of myopathy which varied, but included central migration of nuclei, nuclear clumping and increased variation in muscle fibre size. Some type 1 fibres appeared moth-eaten and in several specimens a proportion of these fibres were reduced in size with mitochondrial clumping and glycogen deficiency. Motor end-plates were little affected but a reduction in synaptic vesicles in a nerve terminal was seen in one patient and elaboration of some end-plates in another.
Muscle contracture was produced in vitro by halothane alone (Cases 1, 2, 4 and 5) and halothane and suxamethonium in combination (Case 3). These are the patients who had positive evi- dence of myopathy histologically. Thus a perfect correlation was obtained between the neuropathological and the neuropharmacological results. Procaine prevented contracture in Cases 2, 3 and 5. It also abolished established contracture. Caffeine increased the force and the rate of development of contracture in susceptible muscle.
Discussion
The neuropathological and neuropharmacological evidence presented suggests that malignant hyperpyrexia may be a manifestation of more than one condition. The histological appearances showed great variation between families. The pharmacological studies revealed that one patient required the halothane-suxamethonium combination to cause contracture while in 4 patients halothane alone sufficed. It is of interest that suxamethonium by itself did not induce contracture in vitro.
The enhancement of caffeine contracture by halothane, which occurs in normal muscle, appears to be of the same order in survivors of malignant hyperpyrexia . This makes interpretation more difficult than the allor-none response we obtained. The finding that procaine modified contracture complements the evidence of its protective effect in susceptible pigs (Harrison 1971) , and is relevant to treatment in the clinical situation where Kalow et al. (1970) have reported successful use of procainamide. Procaine may be acting on damaged sarcoplasmic reticulum but Woolf (personal communication) has shown in pigs that muscle temperature rises before contracture develops. This suggests that a mitochondrial defect may be responsible for the syndrome, which in combination with a raised intracellular Ca++ concentration may lead to 'thermal runaway' in the presence of triggering agents.
We have been unable to induce muscle contracture in vitro with halothane in the classical clinical myopathies. Nor has malignant hyperpyrexia developed in 70 myopathic patients with raised SCPK levels anmsthetized by one of us (F R E) with halothane for muscle biopsy.
The development of muscle contracture in vitro represents a specific abnormal response to certain anesthetic drugs. The correlation between the histological and pharmacological abnormalities encourages us to believe that positive identification of the patient susceptible to malignant hyperpyrexia is possible.
